- Sánchez Fernández I.
- Abend N.S.
- Agadi S.
- et al.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Time from convulsive status epilepticus onset to anticonvulsant administration in children.Neurology. 2015 Jun 9; 84: 2304-2311https://doi.org/10.1212/WNL.0000000000001673
- Factors associated with treatment delays in pediatric refractory convulsive status epilepticus.Neurology. 2018 May 8; 90: e1692-e1701https://doi.org/10.1212/WNL.0000000000005488
- Guidelines for the evaluation and management of status epilepticus.Neurocrit Care. 2012 Aug; 17: 3-23https://doi.org/10.1007/s12028-012-9695-z
- Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.Epilepsy Curr. 2016 Jan-Feb; 16: 48-61https://doi.org/10.5698/1535-7597-16.1.48
- Statewide Emergency Medical Services Protocols for Status Epilepticus Management.Ann Neurol. 2021 Mar; 89: 604-609https://doi.org/10.1002/ana.25989
- Prehospital Treatment of Status Epilepticus in the United States.JAMA. 2021 Nov 16; 326: 1970-1971https://doi.org/10.1001/jama.2021.15964
Publication stageIn Press Journal Pre-Proof
This study and our Consortium were supported by the Epilepsy Foundation of America (EF- 213583, Targeted Initiative for Health Outcomes), the American Epilepsy Society / Epilepsy Foundation of America Infrastructure Award, Pediatric Epilepsy Research Foundation, and the Epilepsy Research Fund.
Potential conflicts of interest
MAG was funded by Fundación Alfonso Martín Escudero and the Epilepsy Research Fund.
ISF was funded by Fundación Alfonso Martín Escudero, the HHV6 Foundation, and the Epilepsy Research Fund.
CBA was funded by Fundación Alfonso Martín Escudero.
TL serves on the Council of the American Clinical Neurophysiology Society, as founder and consortium PI of the pediatric status epilepticus research group (pSERG), as an Associate Editor for Wyllie’s Treatment of Epilepsy 6th edition and 7th editions, and as a member of the NORSE Institute, PACS1 Foundation, and CCEMRC. He is part of patent applications to detect and predict seizures and to diagnose epilepsy. Dr. Loddenkemper is co-inventor of the TriVox Health technology, and Dr. Loddenkemper, and Boston Children’s Hospital might receive financial benefits from this technology in the form of compensation in the future. He received research support from the Epilepsy Research Fund, NIH, the Epilepsy Foundation of America, the Epilepsy Therapy Project, the Pediatric Epilepsy Research Foundation, and received research grants from Lundbeck, Eisai, Upsher-Smith, Mallinckrodt, Sunovion, Sage, Empatica, and Pfizer. He served as a consultant for Zogenix, Upsher Smith, UCB, Grand Rounds, Advance Medical, and Sunovion. He performs video electroencephalogram long-term and ICU monitoring, electroencephalograms, and other electrophysiological studies at Boston Children's Hospital and affiliated hospitals and bills for these procedures and he evaluates pediatric neurology patients and bills for clinical care. He has received speaker honorariums from national societies including the AAN, AES and ACNS, and for grand rounds at various academic centers. His wife, Dr. Karen Stannard, is a pediatric neurologist and she performs video electroencephalogram long-term and ICU monitoring, electroencephalograms, and other electrophysiological studies and bills for these procedures, and she evaluates pediatric neurology patients and bills for clinical care.
The remaining authors have no disclosures relevant to this manuscript.